{
    "clinical_study": {
        "@rank": "115974", 
        "acronym": "TRANEX1", 
        "arm_group": [
            {
                "arm_group_label": "Experimental", 
                "arm_group_type": "Experimental", 
                "description": "Topical administration of 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride) as follow:\n50mL by irrigation before wound closure\n50mL by intraarticular administration (Drenofast) after wound closure.\nIntravenous administration of Normal saline (0.9% sodium chloride) as follow:\n100mL before tourniquet realised\n100mL 3 hours after surgery"
            }, 
            {
                "arm_group_label": "Comparator", 
                "arm_group_type": "Active Comparator", 
                "description": "Topical administration of Normal saline (0.9% sodium chloride) as follow:\n50mL by irrigation before wound closure\n50mL by intraarticular administration (Drenofast) after wound closure\nIntravenous administration of two dosis of Tranexamic Acid as follow:\n15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride),  before  tourniquet realised\n15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), 3 hours after surgery"
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective is to evaluate the efficacy and safety of topical Tranexamic Acid (TA) to\n      reduce the blood transfusion rate in total knee arthroplasty. The secondary endpoints are to\n      estimate the visible blood loss at 24 hours after surgery, and invisible blood loss through\n      serial counting of Hb/Htc. Methodology. TRANEX1 is a phase III, unicentric, controlled,\n      randomized, double blind clinical trial that compare efficacy and safety of topical TA\n      versus intravenous TA in a multimodal protocol, with no-inferiority criteria(n=79)."
        }, 
        "brief_title": "Efficacy Comparison of Topical and Intravenous Tranexamic Acid to Reduce the Number of Blood Transfusions in TKA", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Blood Loss", 
        "condition_browse": {
            "mesh_term": "Hemorrhage"
        }, 
        "detailed_description": {
            "textblock": "The groups will be compared by ITT and PP. The non-inferiority would be estimated by\n      comparing the confidence interval using the traditional test, and Wilson test."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients (greater than 18 years old)\n\n          -  Patients scheduled for primary unilateral knee arthroplasty\n\n          -  Patients for La Paz- Cantoblanco Hospital, Madrid, Spain\n\n        Exclusion Criteria:\n\n          -  Patients that refuse to sign the Inform Consent\n\n          -  Allergy to tranexamic acid\n\n          -  Major comorbidities: Severe ischemic heart disease(class III and IV of New York Heart\n             Association); sleep apnea syndrome; severe EPOC; renal dysfunction (plasma\n             creatinine>2mg/dL if mens and >1.8mg/dL if woman); or hepatic disfunction.\n\n          -  Coagulopathy (preoperative platelet count <150,000/mm3, INR>1.4, prolonged PPT(>1.4 x\n             normal)\n\n          -  History of thromboembolic disease: CVA, DVT, PE\n\n          -  Blood dyscrasias\n\n          -  Retinopathy (disturbances of color vision)\n\n          -  Jehovah's witnesses\n\n          -  Pregnancy\n\n          -  Breastfeeding\n\n          -  Been participating or been participated a year ago in another clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "79", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01881568", 
            "org_study_id": "TRANEX1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Experimental", 
                "description": "Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)", 
                "intervention_name": "Tranexamic Acid", 
                "intervention_type": "Drug", 
                "other_name": "AMCHAFIBRIN"
            }, 
            {
                "arm_group_label": "Comparator", 
                "description": "Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)", 
                "intervention_name": "Tranexamic Acid", 
                "intervention_type": "Drug", 
                "other_name": "AMCHAFIBRIN,"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tranexamic Acid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Total Knee Arthroplasty, TKA, blood loss", 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "contact": {
                "email": "m.ortega.an@gmail.com", 
                "last_name": "Miguel Ortega Andreu, Dr.", 
                "phone": "+34914269774"
            }, 
            "contact_backup": {
                "email": "traumatolog\u00eda.hulp@salud.madrid.org", 
                "last_name": "Servicio Traumatolog\u00eda y Ortopedia", 
                "phone": "+34 917277085/914269752"
            }, 
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28046"
                }, 
                "name": "Hospital Universitario La Paz"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Topical Tranexamic Acid Versus Intravenous Administration to Reduce Blood Transfusion Rate in Total Knee Arthroplasty Surgery: Phase III, Unicentric, Controlled,Double Blind, Randomized Non Inferiority Clinical Trial.", 
        "overall_official": {
            "affiliation": "Hospital Universitario La Paz", 
            "last_name": "Enrique Gomez Barrena, PI", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of transfused patients in each arm/Total number of patients in each arm", 
            "measure": "Blood transfusion rate", 
            "safety_issue": "No", 
            "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 5 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01881568"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Universitario La Paz", 
            "investigator_full_name": "Enrique G\u00f3mez Barrena", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of milliliters drained in Redon after 24 hours post OP", 
                "measure": "Visible blood loss", 
                "safety_issue": "No", 
                "time_frame": "24 hours after surgery"
            }, 
            {
                "description": "Number of milliliters estimated with Nedler formula 48 hours after surgery. Invisible blood loss= 75*weight(Kg)*[(Hb0-Hb1)/Hb0]+ blood transfused(mL)", 
                "measure": "Invisible blood loss", 
                "safety_issue": "No", 
                "time_frame": "48 hours after surgery"
            }, 
            {
                "description": "Percent of patients with proved signs of infection during the hospital stay\nPercent of patients with proved signs of infection one month after surgery(safety reasons)", 
                "measure": "Surgery infection rate", 
                "safety_issue": "Yes", 
                "time_frame": "One month after surgery"
            }, 
            {
                "description": "- Range (in degrees) from full extension to full flexion during the hospital stay", 
                "measure": "Range of motion", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 5 days"
            }, 
            {
                "description": "Rate and characteristics of the adverse events during the hospital stay", 
                "measure": "Prevalence of drug-related adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 5 days"
            }, 
            {
                "description": "Percent of PE during the hospital stay\nPercent of PE one month after surgery(safety reasons)", 
                "measure": "Rate of PE", 
                "safety_issue": "Yes", 
                "time_frame": "One month after surgery"
            }, 
            {
                "description": "Percent of DVT  during the hospital stay\nPercent of DVT  one month after surgery(safety reasons)", 
                "measure": "Rate of DVT", 
                "safety_issue": "Yes", 
                "time_frame": "One month after surgery"
            }, 
            {
                "description": "Percent of Thrombophlebitis during the hospital stay\nPercent of Thrombophlebitis one month after surgery(safety reasons)", 
                "measure": "Rate or Thrombophlebitis", 
                "safety_issue": "Yes", 
                "time_frame": "One month after surgery"
            }
        ], 
        "source": "Hospital Universitario La Paz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Universitario La Paz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}